Report
EUR 13.72 For Business Accounts Only

JINYU BIO-TECH sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of JINYU BIO-TECH (CN), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date July 9, 2021, the closing price was CNY 19.76 and its potential was estimated at CNY 22.57.
Underlying
Jinyu Bio-Technology Co. Ltd. Class A

Inner Mongolia Jinyu Group is engaged in the manufacture of biopharmaceutical products; processing yarn and cashmere products; production of worsted woolen fabric; development and application of high new technology; sale of metal materials, chemical materials, timber, and cement; development and leasing residential and commercial properties; and housing agency. Through its subsidiaries, Co. is engaged in the sale of veterinary medicine; manufacture of knitwear; and property management. Co.'s principal products are veterinary medicine, biopharmaceutical, cashmere products and real estate development.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch